Table 1.

Key clinical data.

Parameters		Scenario 1		Scenario 2
		Classic mode	values	Cure mode	values
Full population	PFS: chemotherapy	Log-logistic	Shape = 2.339 Scale = 9.146	Log-logistic mixture cure	theta = 0.0426 shape = 2.5569 scale = 8.6537
	PFS: sacituzumab govitecan	Log-normal	Meanlog = 2.9889 Sdlog = 1.0169	Log-normal mixture cure	theta = 0.0569 meanlog = 2.8824 sdlog = 0.9411
	OS: chemotherapy	Log-logistic	Shape = 1.904 Scale = 28.350	Log-logistic non-mixture cure	theta = 0.0243 shape = 1.74 scale = 67
	OS: sacituzumab govitecan	Weibull	Shape = 1.424 Scale = 67.278	Weibull mixture cure	theta = 0.1174 shape = 1.5381 scale = 57.0151
BMN population	PFS: Chemotherapy	Log-logistic	Shape = 2.569 Scale = 8.972	Log-logis mixture cure	theta = 0.00241 shape = 2.59 scale = 8.95
	PFS: sacituzumab govitecan	Log-logistic	Shape = 1.770 Scale = 22.097	Weibull mixture cure	theta = 0.0721 shape = 1.4158 scale = 27.8427
	OS: chemotherapy	Log-logistic	Shape = 1.839 Scale = 28.903	Log-logistic mixture cure	theta = 0.00415 shape = 1.85 scale = 28.8
	OS: sacituzumab govitecan	Weibull	Shape = 1.411 Scale = 72.222	Gompertz non-mixture cure	theta = 0.24201 shape = 0.03646 rate = 0.00385
Grade 3 or 4 AEs in the chemotherapy arm			Incidence	Range	Distribution
Fatigue			5.40%	(4.05%–6.75%)	Beta
Leukopenia			5.40%	(4.05%–6.75%)	Beta
Anemia			4.90%	(3.68%–6.13%)	Beta
Neutropenia			33%	(24.75%–41.25%)	Beta
Diarrhea			0.40%	(0.3%–0.5%)	Beta
Febrile neutropenia			2.20%	(1.65%–2.75%)	Beta
Grade 3 or 4 AEs in the sacituzumab govitecan arm
Fatigue			3.10%	(2.33%–3.88%)	Beta
Leukopenia			10.10%	(7.58%–12.63%)	Beta
Anemia			7.80%	(5.85%–9.75%)	Beta
Neutropenia			51.20%	(38.4%–64%)	Beta
Diarrhea			10.50%	(7.88%–13.13%)	Beta
Febrile neutropenia			5.80%	(4.35%–7.25%)	Beta
PFS progression-free survival. OS overall survival. BMN brain metastatic-negative. AEs adverse events.